Evaluating the Prognostic Impact of Anti-β1AR Antibodies and Anti-L-CaC Antibodies in Patients With Dilated Cardiomyopathy

Launched by UNION HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY · Dec 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the impact of specific antibodies—anti-β1AR and anti-L-CaC—on the health outcomes of patients with dilated cardiomyopathy (DCM). DCM is a condition where the heart becomes enlarged and weakened, making it harder to pump blood. Researchers want to understand how these antibodies relate to serious heart issues, such as sudden death or dangerous heart rhythms. The goal is to follow 1,000 patients over three years to gather better information that could help improve treatment and care for people with DCM.

To be eligible for this study, participants must be between 18 and 75 years old, have a diagnosis of dilated cardiomyopathy, and be able to give informed consent. This means they understand the study and agree to participate voluntarily. Patients with serious infections, uncontrolled bleeding, or other significant health issues will not be included, as well as those who are pregnant or breastfeeding. If someone joins the study, they can expect regular check-ups and monitoring over the three-year period, which will help researchers learn more about how these antibodies affect their heart condition and overall health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18-75, any gender
• • 2. Diagnosed with dilated cardiomyopathy
• • 3. Subjects or their legal guardians are fully informed of the nature and risks of the study, participate voluntarily, and sign an informed consent form.
• Exclusion Criteria:
• • 1. Serious uncontrolled infection at enrolment ("uncontrolled" is defined as signs and symptoms of infection that persist without improvement despite antimicrobial or other treatment)
• • 2. Uncontrolled active bleeding at enrollment
• • 3. Pregnancy or breastfeeding
• • 4. Combination of serious diseases affecting survival, such as tumors, with a life expectancy of less than one year
• • 5. Previous heart transplant or implantation of a cardiac assist device
• • 6. Patients with poor compliance who are unable to complete the full course of the study
• • 7. Other conditions (e.g., overstimulation, sensitivity, cognitive impairment, mental illness, or substance abuse/addiction) that, in the judgment of the investigator, may increase the risk to the subject or interfere with the clinical study and judgment of the results.